• Modern RetinaModern Retina
  • Ophthalmology Times
  • Ophthalmology Times EuropeOphthalmology Times Europe
  • Optometry TimesOptometry Times
Ophthalmology Times
Ophthalmology Times
Spotlight
BiosimilarsPresbyopia: A part of Aging and ChallengesTreatment Option for Ocular Itch
Clinical
View MorePresbyopiaAMDCataractCataract TherapeuticsClinical DiagnosisCorneaDMEDry EyeGlaucomaIOLOCTOcular AllergyOcular Surface DiseasePediatricsPtosisRefractiveRetinaTechnologyTherapeuticsUnderstanding Antibiotic Resistance
News
All News
Blogs
COVID-19
Media
Expert Interviews
Medical World News
Podcasts
Viewpoints
Insights
Eyeviews
Case Studies
Business
Health Law & Policy
Money Matters
Personal Finance
Practice Management
Conferences
Conference Coverage
Conference Listing
Conference Recaps
Publications
Digital Edition
Europe Ophthalmology Times
Modern Retina
Supplements and Featured Publications
Resources
CME/CE
Job Board
Sponsored
Partners
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • Contact Us
  • Editorial
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information

© 2022 MJH Life Sciences and Ophthalmology Times. All rights reserved.

Spotlight
  • Biosimilars
  • Presbyopia: A part of Aging and Challenges
  • Treatment Option for Ocular Itch
ClinicalSee All >
  • Presbyopia
  • AMD
  • Cataract
  • Cataract Therapeutics
  • Clinical Diagnosis
  • Cornea
  • DME
  • Dry Eye
  • Glaucoma
  • IOL
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Pediatrics
  • Ptosis
  • Refractive
  • Retina
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Advertise
  • Contact Us
  • Editorial
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.

Privacy

Latest News

Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients

Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate

Technology, people key to improving health outcomes, driving revenue

View More Latest News